Korro Bio Announces Preclinical Results Showing KRRO-111 Potential To Treat Both Lung And Liver Manifestations Of Alpha-1 Antitrypsin Deficiency
Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-foldKRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%,
Korro Bio's experimental medicine worked really well in mice. It fixed the broken protein that causes a serious disease in two different organs.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.